Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1041-1046

  Hughes, Walter T ^a   Shenep, Jerry L ^a   Rodman, John H ^a   Fridland, Arnold ^a   Willoughby, Rodney ^b   Blanchard, Suzette ^c   Purdue, Lynette ^d   Coakley, Dion F ^e   Cundy, Kenneth C ^e   Culnane, Mary ^d   Zimmer, Bonnie ^c   Burchett, Sandra ^f   Read, Jennifer S ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e GILEAD SCIENCES   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADENINE; ADOLESCENT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; PHOSPHONIC ACIDS;

EID: 0034075753     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1041-1046.2000     Document Type: Article

References (25)

1. Balzarini, J., L. Naesens, P. Herdewijn, I. Rosenberg, A. Holy, R. Pauwels, M. Baba, D. G. Johns, and E. DeClercq. 1989. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. USA 84:332-336.
2. Balzarini, J., H. Zhang, P. Herdewijn, D. Johns, and E. DeClercq. 1991. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphosphonylmethoxy) adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88:1499-1503.
3. Balzarini, J., et al. 1990. Potent anti-simian immunodeficiency virus (SIV) activity and pharmacokinetics of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in rhesus monkeys, p. 131-138. In H. Schellekens and M. C. Horzinek (ed.), Animal models in AIDS. Elsevier Science Publications, New York, N.Y.
4. Balzarini, J., L. Naesens, J. Slachmuylders, H. Niphuis, L. Rosenberg, A. Holy, H. Schellekens, and E. DeClercq. 1991. 9-(2-Phosphonylmethoxyethyl) adenine (PMEA) effectively inhibits retrovirus replication in vivo and Simian immunodeficiency virus (SIV) infection in rhesus monkeys. AIDS 5:21-28.
5. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413.
6. Bronson, J. J., H.-T. Ho, H. DeBoeck, K. Woods, I. Ghazzouli, J. C. Martin, and M. J. M. Hitchcock. 1990. Biochemical pharmacology of acyclic nucleotide analogues. Ann. N. Y. Acad. Sci. 616:398.
7. Centers for Disease Control and Prevention. 1994. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbid. Mortal. Weekly Rep. 43(RR-12):1-10.
8. Cundy, K. C. 1994. Oral bioavailability of PMEA (GS-0393) from the prodrug bis-POM PMEA (GS-0840) in HIV-infected patients. A report on data from protocol GS-93-401. Gilead Sciences Study Report DDM-GS-94-401. Gilead Sciences, Inc., Foster City, Calif.
9. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
10. Cundy, K., P. Barditch-Crovo, R. Walker, A. Collier, D. Ebeling, J. Toole, and H. Jaffe. 1995. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 39:2401-2405.
11. Cundy, K. C., J. A. Fishback, J.-P. Shaw, M. Lee, K. F. Soike, G. C. Visor, and W. A. Lee. 1994. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloxyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11:839-843.
12. Cundy, K. C., J.-P. Shaw, and W. A. Lee. 1994. Oral, subcutaneous and intramuscular bioavailability of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in cynomolgus monkeys. Antimicrob. Agents Chemother. 38:365-368.
13. Cundy, K. C., I.-L. Sue, G. C. Visor, J. Mashburn, C. Nakamun, W. A. Lee, and J.-P. Shaw. 1997. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J. Pharm. Sci. 86:1334-1338.
14. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II users guide: pharmacokinetics/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, Calif.
15. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 176: 1517-1523.
16. Gilead Sciences, Inc. 1994. A phase I/II study of the safety, tolerance, pharmacokinetics and anti-HIV activity of 9-[2-(bispivaloyloxymethyl)phosphonomethoxy)ethyl]adenine (bis-POM PMEA) and placebo in HIV-infected patients. Gilead Sciences Protocol GS-94-402. Gilead Sciences, Inc., Foster City, Calif.
17. 3: a multi-center, randomized double blind, and placebo controlled study. JAMA, in press.
18. Shaw, J.-P., and K. S. Cundy. 1993. Biological screens of PMEA prodrugs. Pharm. Res. 10:S294.
19. Shaw, J.-P., and K. C. Cundy. 1994. Oral bioavailability of PMEA from a prototype oral suspension formulation of the prodrug bis(POM)PMEA in fasted male cynomolgus monkeys. Gilead Sciences Study Report DDM-JPS-121593. Gilead Sciences, Inc., Foster City, Calif.
20. Shaw, J.-P., and K. C. Cundy. 1994. Oral bioavailability of PMEA from various formulations of PMEA prodrugs bis(POM)PMEA in fasted male cynomolgus monkeys. Gilead Sciences Study Report DDM-JPS-121593. Gilead Sciences, Inc., Foster City, Calif.
21. Shaw, J.-P., and K. C. Cundy. 1994. Oral bioavailability of PMEA from PMEA prodrugs in cynomolgus monkeys: salicylate esters, bis-POM PMEA sulfate and a clinical tablet formulation of bis-POM PMEA. Gilead Sciences Study Report 94-DDM-0840-001B. Gilead Sciences, Inc., Foster City, Calif.
22. Shaw, J.-P., and K. C. Cundy. 1994. Oral bioavailability of PMEA from PMEA prodrugs in Sprague-Dawley rats. Gilead Sciences Study Report DDM-JPS-121593. Gilead Sciences, Inc., Foster City, Calif.
23. Shaw, J. R., M. S. Louie, K. Krishnamurthy, R. J. Jones, A. M. Bidgood, W. A. Lee, and K. C. Cundy. 1997. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25:362-366.
24. Smith, M. S., E. L. Brian, E. DeClerq, and J. G. Pagano. 1989. Susceptibility of human immunodeficiency virus type-1 replication in vitro to acyclic adenosine analogues and synergy of the analogues with 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 33:1482-1486.
25. Srinivas, R. V., B. L. Robbins, M. C. Connelly, Y. F. Gong, N. Bischofberger, and A. Fridland. 1993. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 37:2247-2250.